Given that many pancreatic cancer patients suffer from diabetes, attention should be given to defining a threshold for hypoglycaemic drugs including SGLT inhibitors to decrease the protumorigenic effect through the inhibition of SGLT-1-induced ROS generation without affecting the toxic effect of oxidative stress on cancer cells. This evidence concerns the gene SLC5A1 and familial pancreatic carcinoma.